Payment overview · 2025
General Payments
$1,602.25
75 reported records · 19 companies
Healthcare provider profile · identity verified
Chike Gregory Onwuka, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · CLINTON, MD · NPI 1013065267
Verified facts
What the public records show
CMS Open Payments records show Chike Gregory Onwuka, M.D. received $1,602.25 in general payments during 2025 across 75 reported records.
AstraZeneca Pharmaceuticals LP accounted for 11.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 31 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Gemtesa, Jardiance, Mounjaro, Ozempic, Paxlovid, Trelegy Ellipta.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Myrbetriq by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 69 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LOKELMA as an associated drug or biological on 6897 records involving 4326 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Lokelma by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 55 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 167 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 57 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 99 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 189 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 324 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Paxlovid by this doctor in 2024.
Sumitomo Pharma America, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported GEMTESA as an associated drug or biological on 61692 records involving 22152 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Gemtesa by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $190.21 | 11.9% | 8 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $153.95 | 9.6% | 7 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $153.69 | 9.6% | 7 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $150.77 | 9.4% | 9 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $148.13 | 9.2% | 13 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $148.05 | 9.2% | 9 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $145.20 | 9.1% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $120.00 | 7.5% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $117.61 | 7.3% | 8 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $69.45 | 4.3% | 2 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $39.50 | 2.5% | 2 | 2025 |
| Organogenesis Inc. | Unresolved — no canonical attribution shown | $29.91 | 1.9% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $25.24 | 1.6% | 1 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $22.10 | 1.4% | 1 | 2025 |
| Viatris Specialty LLC | Unresolved — no canonical attribution shown | $18.66 | 1.2% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $18.40 | 1.1% | 1 | 2025 |
| SCILEX PHARMACEUTICALS INC. | Unresolved — no canonical attribution shown | $18.11 | 1.1% | 1 | 2025 |
| Gilead Sciences, Inc. | Unresolved — no canonical attribution shown | $17.38 | 1.1% | 1 | 2025 |
| Esperion Therapeutics, Inc. | Unresolved — no canonical attribution shown | $15.89 | 1.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,602.25 | 75 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $148.13 | 13 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $145.20 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $139.92 | 6 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $137.94 | 5 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $133.44 | 6 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $126.18 | 4 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $124.98 | 5 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $120.00 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $80.59 | 6 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $80.59 | 6 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $71.07 | 3 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $71.07 | 3 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $71.07 | 3 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $70.96 | 5 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $70.96 | 5 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $69.45 | 2 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $67.46 | 3 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $48.54 | 4 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $46.65 | 3 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $39.50 | 2 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $33.40 | 3 | 2025 |
Source payment records
|
|||||
| PAXLOVID Normalized: paxlovid |
Drug | PFIZER INC. | $31.16 | 2 | 2025 |
Source payment records
|
|||||
| SIMPLIMAX Normalized: simplimax |
Medical Supply | Organogenesis Inc. | $29.91 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $25.24 | 1 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $22.10 | 1 | 2025 |
Source payment records
|
|||||
| TEPEZZA Normalized: tepezza |
Biological | Amgen Inc. | $20.51 | 1 | 2025 |
Source payment records
|
|||||
| YUPELRI Normalized: yupelri |
Drug | Viatris Specialty LLC | $18.66 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $18.40 | 1 | 2025 |
Source payment records
|
|||||
| ZTLido Normalized: ztlido |
Drug | SCILEX PHARMACEUTICALS INC. | $18.11 | 1 | 2025 |
Source payment records
|
|||||
| NEXLETOL Normalized: nexletol |
Drug | Esperion Therapeutics, Inc. | $15.89 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE Normalized: freestyle libre |
Device | Abbott Laboratories | $13.77 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 324 | exact normalized | Medicare Part D |
| GEMTESA gemtesa |
2025 | Gemtesa | 2024 | 29 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 167 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 57 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 189 | exact normalized | Medicare Part D |
| PAXLOVID paxlovid |
2025 | Paxlovid | 2024 | 22 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 55 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
26 | 11 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
69 | 21 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | LOKELMA open payments reported associated product |
CMS Open Payments — General Payments 6897 supporting records · 4326 recipient NPIs · example record 1206131624 |
Lokelma · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
55 | 22 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
167 | 54 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
57 | 16 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
99 | 30 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
189 | 60 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
324 | 99 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
22 | 22 |
| Sumitomo Pharma America, Inc. Exact reporting entity; no affiliate inference |
2025 | GEMTESA open payments reported associated product |
CMS Open Payments — General Payments 61692 supporting records · 22152 recipient NPIs · example record 1176593503 |
Gemtesa · 2024 Exact normalized brand match · 1 Part D row |
29 | 14 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Amlodipine Besylate | Amlodipine Besylate | 1141 | 366 |
| Atorvastatin Calcium | Atorvastatin Calcium | 838 | 274 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 554 | 189 |
| Metoprolol Succinate | Metoprolol Succinate | 367 | 129 |
| Eliquis | Apixaban | 324 | 99 |
| Gabapentin | Gabapentin | 302 | 109 |
| Losartan Potassium | Losartan Potassium | 293 | 96 |
| Levothyroxine Sodium | Levothyroxine Sodium | 289 | 84 |
| Carvedilol | Carvedilol | 252 | 83 |
| Metformin Hcl | Metformin Hcl | 236 | 77 |
| Omeprazole | Omeprazole | 229 | 79 |
| Hydrochlorothiazide | Hydrochlorothiazide | 227 | 81 |
| Glimepiride | Glimepiride | 224 | 72 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 214 | 73 |
| Ozempic | Semaglutide | 189 | 60 |
| Allopurinol | Allopurinol | 188 | 58 |
| Metformin Hcl Er | Metformin Hcl | 173 | 59 |
| Nifedipine Er | Nifedipine | 170 | 53 |
| Torsemide | Torsemide | 168 | 64 |
| Jardiance | Empagliflozin | 167 | 54 |
| Pantoprazole Sodium | Pantoprazole Sodium | 161 | 65 |
| Clopidogrel | Clopidogrel Bisulfate | 137 | 43 |
| Furosemide | Furosemide | 137 | 48 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 136 | 69 |
| Mirtazapine | Mirtazapine | 135 | 37 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 128 | 38 |
| Spironolactone | Spironolactone | 125 | 42 |
| Prednisone | Prednisone | 124 | 66 |
| Pravastatin Sodium | Pravastatin Sodium | 121 | 37 |
| Lisinopril | Lisinopril | 116 | 39 |
| Montelukast Sodium | Montelukast Sodium | 115 | 34 |
| Metoprolol Tartrate | Metoprolol Tartrate | 114 | 40 |
| Duloxetine Hcl | Duloxetine Hcl | 110 | 46 |
| Labetalol Hcl | Labetalol Hcl | 106 | 39 |
| Tamsulosin Hcl | Tamsulosin Hcl | 104 | 36 |
| Trulicity | Dulaglutide | 99 | 30 |
| Memantine Hcl | Memantine Hcl | 96 | 24 |
| Escitalopram Oxalate | Escitalopram Oxalate | 93 | 29 |
| Trazodone Hcl | Trazodone Hcl | 92 | 26 |
| Tresiba Flextouch U-200 | Insulin Degludec | 91 | 30 |
| Potassium Chloride | Potassium Chloride | 89 | 32 |
| Fluticasone Propionate | Fluticasone Propionate | 88 | 46 |
| Hydralazine Hcl | Hydralazine Hcl | 87 | 34 |
| Famotidine | Famotidine | 86 | 33 |
| Methylprednisolone | Methylprednisolone | 82 | 65 |
| Atenolol | Atenolol | 79 | 23 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 77 | 65 |
| Finasteride | Finasteride | 77 | 24 |
| Colchicine | Colchicine | 75 | 29 |
| Valsartan | Valsartan | 72 | 21 |
| Ezetimibe | Ezetimibe | 71 | 24 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 70 | 24 |
| Farxiga | Dapagliflozin Propanediol | 69 | 21 |
| Celecoxib | Celecoxib | 68 | 24 |
| Donepezil Hcl | Donepezil Hcl | 68 | 25 |
| Simvastatin | Simvastatin | 67 | 25 |
| Meloxicam | Meloxicam | 66 | 31 |
| Ondansetron Hcl | Ondansetron Hcl | 66 | 33 |
| Cefuroxime | Cefuroxime Axetil | 65 | 58 |
| Glipizide | Glipizide | 65 | 19 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 62 | 18 |
| Candesartan Cilexetil | Candesartan Cilexetil | 61 | 20 |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 59 | 47 |
| Mounjaro | Tirzepatide | 57 | 16 |
| Bumetanide | Bumetanide | 56 | 31 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 55 | 22 |
| Xarelto | Rivaroxaban | 55 | 15 |
| Verapamil Er | Verapamil Hcl | 53 | 16 |
| Irbesartan | Irbesartan | 50 | 17 |
| Tizanidine Hcl | Tizanidine Hcl | 48 | 31 |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 46 | 16 |
| Januvia | Sitagliptin Phosphate | 46 | 17 |
| Lansoprazole | Lansoprazole | 46 | 15 |
| Sertraline Hcl | Sertraline Hcl | 45 | 15 |
| Buspirone Hcl | Buspirone Hcl | 42 | 11 |
| Naproxen | Naproxen | 42 | 26 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 41 | 14 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 39 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 38 | 17 |
| Tresiba Flextouch U-100 | Insulin Degludec | 38 | 14 |
| Meclizine Hcl | Meclizine Hcl | 37 | 16 |
| Azithromycin | Azithromycin | 36 | 31 |
| Benazepril Hcl | Benazepril Hcl | 36 | 11 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 36 | 24 |
| Tramadol Hcl | Tramadol Hcl | 36 | 21 |
| Glipizide Er | Glipizide | 35 | 13 |
| Levetiracetam | Levetiracetam | 35 | 15 |
| Alendronate Sodium | Alendronate Sodium | 34 | 12 |
| Entresto | Sacubitril/Valsartan | 34 | suppressed |
| Clonazepam | Clonazepam | 33 | 11 |
| Doxycycline Hyclate | Doxycycline Hyclate | 33 | 28 |
| Lidocaine | Lidocaine | 33 | 17 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 31 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 30 | 23 |
| Clonidine Hcl | Clonidine Hcl | 30 | suppressed |
| Clotrimazole | Clotrimazole | 29 | 19 |
| Fluconazole | Fluconazole | 29 | 16 |
| Gemtesa | Vibegron | 29 | 14 |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 28 | 11 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 28 | suppressed |
| Eplerenone | Eplerenone | 28 | 11 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 28 | suppressed |
| Lactulose | Lactulose | 28 | 16 |
| Sod Sulf-Potass Sulf-Mag Sulf | Sodium, Potassium,mag Sulfates | 28 | 24 |
| Candesartan-Hydrochlorothiazid | Candesartan/Hydrochlorothiazid | 27 | suppressed |
| Risperidone | Risperidone | 27 | suppressed |
| Synthroid | Levothyroxine Sodium | 27 | suppressed |
| Myrbetriq | Mirabegron | 26 | 11 |
| Tradjenta | Linagliptin | 26 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 26 | 20 |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 25 | 11 |
| Chlorthalidone | Chlorthalidone | 25 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 25 | suppressed |
| Linzess | Linaclotide | 24 | suppressed |
| Lokelma | Sodium Zirconium Cyclosilicate | 24 | suppressed |
| Lorazepam | Lorazepam | 24 | 15 |
| Metronidazole | Metronidazole | 24 | 19 |
| Pregabalin | Pregabalin | 24 | suppressed |
| Spironolactone-Hctz | Spironolact/Hydrochlorothiazid | 24 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 24 | 15 |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 23 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 23 | 17 |
| Pioglitazone Hcl | Pioglitazone Hcl | 23 | suppressed |
| Ibuprofen | Ibuprofen | 22 | 12 |
| Mupirocin | Mupirocin | 22 | 15 |
| Paxlovid | Nirmatrelvir/Ritonavir | 22 | 22 |
| Amitriptyline Hcl | Amitriptyline Hcl | 21 | suppressed |
| Betamethasone Diprop Augmented | Betamethasone/Propylene Glyc | 21 | 13 |
| Diazepam | Diazepam | 21 | 12 |
| Diclofenac Sodium | Diclofenac Sodium | 21 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 21 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 21 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 21 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 20 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 20 | 14 |
| Primidone | Primidone | 20 | suppressed |
| Telmisartan | Telmisartan | 20 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 19 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 19 | suppressed |
| Topiramate | Topiramate | 19 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 18 | suppressed |
| Synjardy | Empagliflozin/Metformin Hcl | 18 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 18 | suppressed |
| Fenofibrate | Fenofibrate | 17 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 17 | suppressed |
| Methocarbamol | Methocarbamol | 17 | 11 |
| Ondansetron Odt | Ondansetron | 17 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 16 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 16 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 16 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 16 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 15 | suppressed |
| Kapspargo Sprinkle | Metoprolol Succinate | 15 | suppressed |
| Metolazone | Metolazone | 15 | suppressed |
| Novolog Flexpen | Insulin Aspart | 15 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 15 | suppressed |
| Telmisartan-Hydrochlorothiazid | Telmisartan/Hydrochlorothiazid | 15 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 15 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 14 | suppressed |
| Cilostazol | Cilostazol | 14 | suppressed |
| Dilt-Xr | Diltiazem Hcl | 14 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 14 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 14 | suppressed |
| Scopolamine | Scopolamine | 14 | suppressed |
| Advair Diskus | Fluticasone Propion/Salmeterol | 13 | suppressed |
| Alprazolam | Alprazolam | 13 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 13 | suppressed |
| Ramipril | Ramipril | 13 | suppressed |
| Veltassa | Patiromer Calcium Sorbitex | 13 | suppressed |
| Carbamazepine Er | Carbamazepine | 12 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 12 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 12 | suppressed |
| Hydrocortisone | Hydrocortisone | 12 | suppressed |
| Isosorbide Dinit-Hydralazine | Isosorbide Dinit/Hydralazine | 12 | suppressed |
| Klor-Con M20 | Potassium Chloride | 12 | suppressed |
| Nystatin | Nystatin | 12 | suppressed |
| Paroxetine Er | Paroxetine Hcl | 12 | suppressed |
| Ketoconazole | Ketoconazole | 11 | suppressed |
| Repaglinide | Repaglinide | 11 | suppressed |
| Tramadol Hcl-Acetaminophen | Tramadol Hcl/Acetaminophen | 11 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,602.25 · 75 records | AstraZeneca Pharmaceuticals LP | ABRYSVO, AIRSUPRA, BREZTRI, COMIRNATY, Cologuard Collection Kit, Dexcom G6 Transmitter, ELIQUIS, FREESTYLE LIBRE, FREESTYLE LIBRE 3, GEMTESA, JARDIANCE, Kerendia, Korlym, MOUNJARO, NEXLETOL, NURTEC ODT, OTEZLA, Ozempic, PAXLOVID, PREVNAR 20, REPATHA, REXULTI, Rybelsus, SIMPLIMAX, TEPEZZA, TRELEGY ELLIPTA, Veozah, Wegovy, YUPELRI, ZEPBOUND, ZTLido | 11 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Astellas Pharma US Inc?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error